Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$10.63 ▼ -0.13
(-1.21%)
MKT CAP: $918.0M • VOL: 1.77M
52W L $10 52W H $26
ROARABLE / RQD
E • 25/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$9
MEDIAN
$12
MEAN
$12
HIGH
$14
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE GLUE TAPE
GLUE // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $12.86 | $12.22 | 2025-02-14 | $9.67 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $13.39 | $12.54 | 2025-02-06 | $9.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $12.12 | $11.69 | 2025-01-29 | $10.20 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $10.84 | — | 2025-01-17 | $10.42 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $9.35 | $10.10 | 2025-01-09 | $9.46 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $12.65 | $11.06 | 2024-12-18 | $9.25 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $10.31 | $10.74 | 2024-12-04 | $9.89 | -4.3% | 48% | C |